Methods and compositions associated with the granulocyte colony-stimulating factor receptor

Patent metadata

Field	Value
Publication number	US-11413274-B2
Application number	US-202016925926-A
Country	US
Kind code	B2
Filing date	Jul 10, 2020
Priority date	Nov 14, 2011
Publication date	Aug 16, 2022
Grant date	Aug 16, 2022

Abstract

Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders.

First claim

What is claimed is:

1. A compound of Formula (IIb) having the following structure:

a tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein
R 3 is selected from hydrogen, an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 3 -C 8 cycloalkyl, an optionally substituted C 1 -C 6 heterocycle, an optionally substituted aryl, and an optionally substituted heteroaryl;
R 4 is selected from an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 3 -C 8 cycloalkyl, an optionally substituted C 1 -C 6 heterocyclyl; and
R 9 is selected from hydrogen, an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 3 -C 8 cycloalkyl, an optionally substituted C 1 -C 6 heterocyclyl, an optionally substituted heteroaryl, an optionally substituted arylalkyl, and an optionally substituted heteroarylalkyl.

2. The compound of claim 1 , wherein:
R 3 is selected from hydrogen, and an optionally substituted C 1 -C 3 alkyl;
R 4 is selected from an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 3 -C 8 cycloalkyl; and
R 9 is selected from an optionally substituted C 1 -C 6 alkyl, an optionally substituted arylalkyl, an optionally substituted arylalkenyl, an optionally substituted arylalkynyl, and an optionally substituted heteroarylalkyl.

3. The compound of claim 2 , wherein:
R 3 is an optionally substituted C 1 -C 3 alkyl;
R 4 is an optionally substituted C 1 -C 4 alkyl; and
R 9 is selected from an optionally substituted C 1 -C 3 alkyl, an optionally substituted arylalkyl, an optionally substituted arylalkenyl, and an optionally substituted arylalkynyl.

4. The compound of claim 3 , wherein R 3 is a C 1 -C 4 alkyl.

5. The compound of claim 4 , wherein R 3 is methyl.

6. The compound of claim 3 , wherein R 4 is a C 1 -C 4 alkyl substituted with hydroxy, cyano, or phenyl.

7. The compound of claim 6 , wherein R 4 is a C 1 -C 4 alkyl substituted with hydroxy.

8. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.

Assignees

• Ligand Pharm Inc

Inventors

• Zhi Lin
• Marschke Keith
• Grant Virginia H
• Roach Steven L
• Shen Yixing
• Pickens Jason C
• Pedram Bijan
• Van Oeveren Cornelis Arjan
• Valdez Lino J
• Hudson Andrew R

Classifications

• C07D405/06

  linked by a carbon chain containing only aliphatic carbon atoms · CPC title

• C12Q1/66

  involving luciferase · CPC title

• C07D231/52

  Oxygen atom in position 3 and nitrogen atom in position 5, or vice versa · CPC title

• A61K31/454

  containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone · CPC title

• C12Q1/18

  Testing for antimicrobial activity of a material · CPC title